Key Points of the 2019 Japanese Society of Hypertension Guidelines for the Management of Hypertension
- Author:
Kazuomi KARIO
1
Author Information
- Publication Type:Review
- Keywords: Hypertension; Evidence-based practice; Antihypertensive agents; Japan
- MeSH: Aged; Antihypertensive Agents; Asian Continental Ancestry Group; Blood Pressure; Delivery of Health Care; Evidence-Based Practice; General Practitioners; Heart Failure; Humans; Hypertension; Japan; Medical Informatics; Stroke
- From:Korean Circulation Journal 2019;49(12):1123-1135
- CountryRepublic of Korea
- Language:English
- Abstract: The new 2019 Japanese Society of Hypertension (JSH) guidelines for the management of hypertension are now available; these update the previous guidelines published in 2014. The primary objective of the guideline is to provide all healthcare professionals with a standard management strategy and appropriate antihypertensive treatments to prevent hypertension-related target organ damage and cardiovascular events. The major changes in the new guideline relate to the definition of normal blood pressure (BP) and target BP. The terms ‘normal BP’ and ‘high normal BP’ used in the JSH 2014 guidelines are replaced with terms ‘high normal BP’ and ‘elevated BP,’ respectively. There was no change to the office BP diagnostic threshold for hypertension (140/90 mmHg). Recommended target office and home BP values for patients with hypertension aged <75 years and/or high-risk patients are <130/80 mmHg and <125/75 mmHg, respectively. Corresponding targets for elderly patients with hypertension (age≥75 years) are 140/90 and 135/85 mmHg, respectively. The goal is that these changes will contribute to reducing cardiovascular events, especially stroke and heart failure, in Japan. The dissemination of the JSH 2019 guidelines and implementation of a home BP-based approach by all general practitioners in Japan might be facilitated by digital hypertension management using health information technology.
